Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Apr 15, 2026
TickeronGET DAILY SIGNALS
Albertsons (ACI) Q4 Earnings: Resilience Amid Pharmacy Pressures and Solid Guidance

Albertsons (ACI) Q4 Earnings: Resilience Amid Pharmacy Pressures and Solid Guidance

Key Takeaways

  • Albertsons reported Q4 fiscal 2025 net sales and other revenue of $20.3 billion, up from $18.8 billion in the prior-year 12-week period, boosted by a 53rd week.
  • Identical sales grew 0.7%, pressured by pharmacy headwinds from the Inflation Reduction Act (IRA, a U.S. law capping certain drug prices) and GLP-1 (glucagon-like peptide-1 drugs for diabetes/weight loss) mix shifts.
  • Adjusted EBITDA reached $903 million, exceeding expectations despite challenges; full-year adjusted EBITDA hit $3.9 billion.
  • Adjusted EPS was $0.48, beating consensus estimates of $0.43 by $0.05.
  • Net loss of $481 million due to a $600 million opioid settlement charge; shares fell over 3% post-earnings.
  • FY2026 guidance includes identical sales of 0%-1%, adjusted EBITDA of $3.85-$3.925 billion, and raised dividend plus $2 billion buyback authorization.

Earnings Context and Why It Matters to Investors

As someone who follows the grocery and pharmacy space closely, I see Albertsons Companies (ACI)—one of the largest U.S. food and drug retailers with over 2,200 stores—navigating a tough competitive landscape from players like Walmart, Costco, and Amazon. This Q4 fiscal 2025 report, which ended February 28, 2026, wraps up a year marked by macroeconomic pressures, digital acceleration, and regulatory shifts like the IRA affecting reimbursements. From what I see, investors are paying particular attention to pharmacy dynamics, now a critical growth area, and identical sales trends as indicators of consumer health. The strong adjusted profitability highlights operational efficiency, but factors like the opioid settlement and forward guidance will influence perceptions around capital returns and potential mergers in this consolidating industry.

Breaking Down the Reported Results

Albertsons delivered net sales and other revenue of $20.3 billion for the 13-week Q4 fiscal 2025, compared to $18.8 billion in the prior-year 12-week quarter. This uptick included about $1.4 billion from the extra 53rd week, plus 0.7% identical sales growth. Digital sales increased 16%, though pharmacy sales encountered steeper-than-expected headwinds: roughly 105 basis points from IRA pricing and 40 basis points from GLP-1 moderation, totaling around 145 basis points of impact.

Adjusted EBITDA rose to $903.4 million (including about $68 million from the extra week), up from $855.1 million last year and ahead of analyst forecasts. Adjusted net income came in at $252 million, or $0.48 per share, surpassing the consensus of $0.43. On a GAAP basis, though, the company posted a net loss of $480.8 million, or ($0.94) per share, primarily due to a $599.8 million pre-tax opioid settlement charge. For the full year, net sales reached $83.2 billion, up from $80.4 billion, with 2% identical sales growth and adjusted EBITDA of $3.9 billion.

One thing that stands out here is how the adjusted metrics held up well despite the pharmacy pressures—I also checked this using Tickeron’s AI Screener to compare ACI against peers in the industry.

Market Reaction and Investor Sentiment

Post-earnings on April 14, 2026, ACI shares declined 3.03% to $16.34, with further drops in after-hours and premarket trading. The reaction seemed driven by revenue coming in slightly below some estimates (around $20.3 billion versus $20.49 billion expected in certain spots), pharmacy challenges surpassing forecasts, and the opioid charge eclipsing the positive adjusted EPS and EBITDA results. Even with supportive capital return moves—a 13% dividend increase to $0.17 per share and a reset $2 billion buyback—sentiment has turned cautious amid broader grocery sector issues like margin compression.

Forward Outlook and Factors I'm Watching

Looking ahead, Albertsons provided fiscal 2026 guidance for a 53-week year ending around February 2027, forecasting identical sales growth of 0%-1% (or 1.5%-2.5% excluding IRA impacts). This reflects persistent pharmacy reimbursement issues and easing GLP-1 demand.

Adjusted EBITDA is projected at $3.85-$3.925 billion, bolstered by a $2 billion three-year productivity program, AI and digital investments, and supply chain improvements. The adjusted EPS range is $2.22-$2.32, with capital expenditures of $2.0-$2.2 billion earmarked for remodels (94 completed in FY2025), new stores, and technology platforms. The effective tax rate is expected at 24%-25%.

In my view, key areas to monitor include pharmacy trends under the IRA, digital and loyalty program growth (with 49.8 million members previously), fuel margins, and Own Brands performance in an inflationary environment. Capital allocation will remain pivotal—FY2025 returned over $1.8 billion through buybacks and dividends, and the new authorization signals confidence. Broader opportunities could emerge from M&A in the fragmented grocery sector, labor trends, and consumer spending patterns.

Why I Use Tickeron’s AI Screener in My Analysis

As part of my regular research process, I rely on Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—such as industry peers, market cap, indicators, price patterns, and performance metrics. This helps pinpoint trade ideas, trending stocks, breakouts, and opportunities far more efficiently than manual methods. If you're screening for names like ACI, it's a practical way to streamline your workflow.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: ACI

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ACI's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for ACI moved out of overbought territory on October 28, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In 17 of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACI as a result. In 54 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.

The Moving Average Convergence Divergence Histogram (MACD) for ACI turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 27 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.

ACI moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for ACI crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 40%.

Following a +3.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACI advanced for three days, in 143 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.

ACI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 66 of 143 cases where ACI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 46%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. ACI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.849) is normal, around the industry mean (59198.906). ACI's P/E Ratio (79.938) is considerably higher than the industry average of (11.813). Projected Growth (PEG Ratio) (1.212) is also within normal values, averaging (0.979). ACI's Dividend Yield (0.053) is considerably higher than the industry average of (0.016). P/S Ratio (0.080) is also within normal values, averaging (10.259).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

Notable companies

The most notable companies in this group are Kroger Co (The) (NYSE:KR).

Industry description

The food retail industry includes companies that sell food, beverage and household products. Items sold include grocery, gourmet food, fresh produce, and frozen food. Kroger Co., George Weston Ltd., Grocery Outlet Holding Corp., and Sprouts Farmers Markets, Inc. are examples of major food retailers. While e-commerce companies like Amazon have increasingly been ramping-up offerings in the food retail space, several traditional players have also been expanding their online presence to stand their ground against rising competition.

Market Cap

The average market capitalization across the Food Retail Industry is 4.52B. The market cap for tickers in the group ranges from 80 to 51.42B. LBLCF holds the highest valuation in this group at 51.42B. The lowest valued company is MFLTY at 80.

High and low price notable news

The average weekly price growth across all stocks in the Food Retail Industry was -6%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -19%. MSS experienced the highest price growth at 21%, while YSWY experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Food Retail Industry was 368%. For the same stocks of the Industry, the average monthly volume growth was 256% and the average quarterly volume growth was 246%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 53
Price Growth Rating: 62
SMR Rating: 74
Profit Risk Rating: 76
Seasonality Score: -6 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in production and distribution of thermal coal

Industry FoodRetail

Industry
N/A
Address
250 Parkcenter Boulevard
Phone
+1 208 395-6200
Employees
280000
Web
https://www.albertsonscompanies.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.